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Metformin in Cervical Cancer: 
Metabolic Reprogramming
Malgorzata Tyszka-Czochara and Marcin Majka
Abstract
The reprogrammed metabolism plays a crucial role in intensively proliferating 
tumor cells to meet high energetic demands and adapt to metastasis and invasion. 
Metformin may counteract flexible metabolic phenotype of cervical cancer cells by 
restraining aerobic glycolysis (Warburg effect) and promoting mitochondrial-based 
metabolism. Metformin inhibits master oncogene c-Myc as well as hypoxia-induc-
ible factor 1 (HIF-1α) and suppresses its downstream glycolytic regulatory enzymes 
and glucose transporters. Metformin targets bioenergetics of cervical cancer cells 
with aggressive phenotype and regulates the expression of enzymes controlling 
tricarboxylic acid cycle (TCA cycle) supplementation with substrates, glucose, 
and glutamine. The exposition of cervical tumor cells to Metformin alleviates their 
migratory capacity, restrains epithelial-to-mesenchymal transition (EMT) program 
implementation, and elucidates oxidative stress, which results in massive cell death 
due to apoptosis. The metabolic alterations caused by Metformin are specific to 
cancer cells. In summary, Metformin exerts antitumor effect in cervical cancer cells 
by regulating specific molecular targets in reprogrammed metabolism. Metformin 
selectively modulates metabolic pathways and thus may be potentially used in new 
precisely targeted therapeutic strategies for cervical cancer.
Keywords: Metformin, cancer, metabolism, metabolic reprogramming,  
Warburg effect, mitochondria, apoptosis, oncogenes, reactive oxygen species, 
epithelial-mesenchymal transition, targeted anticancer therapy
1. Introduction
The malignant transformation results in a specific rearrangement of meta-
bolic processes called metabolic reprogramming of tumor cell. The altered 
metabolism causes a selective advantage to a transformed cell by facilitating its 
survival in a harsh environment and promoting the spread of tumor cells within 
the body.
Malignant cells very effectively adapt to high proliferation rate, metastasis, and 
invasion. Several molecular mechanisms were pointed out to drive such metabolic 
adaptation of cancer cells. The critical aspects of metabolic reprogramming in 
tumor cells substantially contribute to the Warburg effect [1], an increased catabo-
lism of glucose to lactate in the presence of oxygen [2]. The altered metabolism 
of tumors results in elevated biosynthesis of macromolecules such as proteins, 
carbohydrates, and lipids and, in consequence, supports high proliferation rate of 
malignant cells [3].
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In particular, the regulation of mitochondrial processes in cancer cells dif-
fers from normal counterparts, and it may be specific to the stage of tumor [4]. 
Therefore, cancer cells are sensitive to drugs that disrupt energy homeostasis, such 
as Metformin (1,1-dimethylbiguanide, Met) [5].
A generic drug, Metformin, has been widely used for treatment of diabetes 
mellitus in humans. However, it exerts pleiotropic effect in human organism. 
In particular, a great interest has been paid to Met, since retrospective analyses 
demonstrated that it significantly decreased the relative risk of cancer incidence in 
diabetic patients when compared with patients treated with other drugs. Clinical 
trials confirmed the epidemiological observations that Met exerted anticancer 
effects in humans [6]. It has been established that Met inhibits proliferation of 
various neoplastic cell lines in vitro, including breast, prostatic, colon, gastric, and 
cervical cancers [7, 8]. Currently, there is an intense ongoing research focused on 
molecular mechanisms behind these effects, since the implications of Met action in 
tumor cell are not completely understood [9].
To date, several molecular mechanisms were reported to play critical role in 
anticancer activity of Met. In particular, it was established that Met may affect 
energy metabolism of cancer cells by inhibition of complex I of mitochondrial 
electron transport chain (ETC) in mitochondria, which results in adenosine-5′-
triphosphate (ATP) depletion and remodeling of the network of biosynthetic 
processes within the cell [9]. Met may act as an anticancer drug through the 
activation of the main energy regulator within the cell, adenosine 5′-monophos-
phate (AMP)-activated protein kinase (AMPK) [7], and inhibition of mechanistic 
target of rapamycin complex-1 (mTORC1) [10] in tumor cells. Some of the 
pharmacological effects of Met seem to be independent of its action on glycemia 
homeostasis. Several reports demonstrated that treatment of tumor cells with Met 
results in cell cycle perturbations and apoptosis [11, 12]. The intracellular targets 
affected by Met were comprehensively reviewed by Ikhlas and Ahmad [9] and 
Pierotti et al. [13].
Along with the advent of human papillomavirus (HPV) vaccines, the primary 
prevention of cervical cancer has become more successful, but cervical malig-
nancy still remains the significant cause of cancer mortality in women worldwide. 
Currently, chemotherapy using cytostatic drugs (mainly cisplatin, cis-dichloro-
diammineplatinum (II)) is still the primal regimen, despite low specificity and 
substantial toxicity in patients [14].
Aerobic glycolysis has been recognized as the most common metabolic feature 
of malignant cells. The alterations in metabolism of cancer cells combined with 
the overexpression of oncogenes (c-Myc) and transcription factors (hypoxia-
inducible factor 1a, HIF 1a) confer a great advantage to malignant cells to avoid 
apoptosis induced by reactive oxygen species (ROS). In this study we focused 
on the effects of Met on metabolism of metastatic cervical tumor cells. Based 
on recent data, we reported that Met inhibited glycolytic phenotype of aggres-
sive cervical cancer cells by regulation of expression of oncogenes and their 
downstream proteins, which led to cellular death. Furthermore, Met regulated 
mitochondrial metabolism, especially via supplementation of tricarboxylic acid 
cycle (TCA cycle, Krebs cycle) with pyruvate and glutamine. Met, by targeting 
epithelial and mesenchymal markers of tumor cells, alleviated invasive properties 
of cervical cancer cells.
This review summarizes recent findings on Met and cervical cancer underscor-
ing new implications of this drug in regulation of peculiar metabolism of tumor 
cells. We discuss new perspectives about targeting specific alterations in cervical 
tumor metabolic pathways using Met.
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2.  Metformin regulates metabolism of metastatic cervical cancer  
cells in vitro study
A growing evidence suggests that the screening for molecular targets for anti-
cancer therapeutic treatments should take into account the existing differences 
in tumor cell phenotypes. Therefore, the metabolic effects exerted by Met were 
studied using SiHa cells (American Type Culture Collection, ATCC designation 
HTB-35) originating from aggressive cervical tumor, which acquired malignant 
characteristics [15]. The regulation of apoptosis pathways in HTB-35 (SiHa) cells 
highly reflects the specificity of cervical tumor in vivo [16]. HTB-35 cells, even 
unstimulated with cytokines, have mesenchymal-like characteristics, especially 
high vimentin expression, along with enhancement of cell scattering and ability to 
move [17]. Another cell line, C-4I cells (ATCC, designation CRL1594) with epithe-
lial phenotype, was derived from primary in situ tumor [18]. HTB-34 cells (ATCC 
designation MS751) were isolated from metastatic site in lymph node [19]. HTB-35, 
C-4I and HTB-34 are human squamous cell cervical carcinoma lines and it is worth 
noting that squamous cell cancer is the most common cervical cancer and accounts 
for almost 80% of cervical carcinomas in patients [14]. HeLa human cervical cancer 
cells (ATCC designation CCL 2), which have been extensively used in mechanistic 
studies, expressed epithelial traits and were derived from adenocarcinoma [8].
2.1  Metformin hampers the expression of oncogenes controlling glycolytic 
phenotype of cervical cancer cells under hypoxic and normoxic conditions 
and promotes apoptosis
The reliance on glucose supply is linked to the aggressiveness of malignant cells. 
Such reprogrammed metabolism makes migrating cancer cells more robust and 
independent of environmental conditions. The dysregulation of glucose metabolism 
is caused by alterations in functioning of several oncogenes. Malignant cells may 
gain metabolic plasticity by upregulation of only few oncogenes, such as c-Myc, p53, 
phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) 
[20]. Additionally, the activation of transcription factors, such as HIF-1α, makes 
malignant cells more resistant to hypoxia (decreased oxygen level in microenviron-
ment), which is one of the main factors affecting tumor growth [20]. The activation 
of HIF-1α is one of the crucial processes that promote glycolysis to generate ATP 
along with the decrease of mitochondrial pathways’ activity in aggressive tumors. 
What is more, the migrating tumor cells may avoid oxidative stress by relying on 
glucose catabolism. As a result, tumor cells have higher chance to survive detach-
ment from extracellular matrix (ECM), whereas normal cells undergo programmed 
death due to anoikis in the absence of attachment to ECM [21]. Following detach-
ment from primary tumor bed and transportation to plasma and lymph, malignant 
cells may spread within the body and form secondary tumors. Therefore, the 
reprogrammed metabolism plays a crucial role in facilitating tumor metastasis.
We found that Met may regulate glycolysis in aggressive cervical cancer cells. 
The glycolytic phenotype of tumor cells is triggered mainly by a master regulator 
HIF-1α and its downstream proteins. Our study showed that Met alleviated the 
hypoxia-induced activation of HIF-1α, which was followed by decreased expression 
of HIF-1α downstream protein effectors in HTB-35 cells, as demonstrated in [22]. In 
particular, Met downregulated GLUT transporters (solute carrier family 2 member 
receptors, SLC2A), specifically GLUT1 and GLUT3. Additionally, Met inhibited the 
regulatory enzymes of the glycolytic pathway, hexokinase 2 (HK2), bifunctional 
enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4), 
Metformin
4
pyruvate kinase (PKM), and lactate dehydrogenase (LDH) (Figure 1). Met exerted 
greater effect on regulatory proteins in HTB-35 cells exposed to decreased oxygen 
level in the air than normal conditions.
Recent studies have reported that overexpression of c-Myc oncogene plays a sig-
nificant role in the formation of cervical cancer. The enhanced expression of c-Myc 
is also of particular relevance to promoting invasive phenotype of cancer cells. 
What is more, the upregulated c-Myc may collaborate with HIF to effectively induce 
glucose and glutamine consumption in tumor cells. As a result, mitochondrial 
oxidative phosphorylation decreases. In particular, the upregulated c-Myc enhances 
glutamine catabolism in tumor cells, since the oncogene controls glutaminase (GLS) 
expression [23]. As measured using qPCR analysis, Met decreased c-MYC transcript 
level in HTB-35 cells [22], which was in compliance with inhibition of GLS protein 
expression [11]. The treatment of cervical tumor cells with Met decreased mRNA 
level for another c-Myc downstream protein, CCND1 (cyclin D1), which regulates 
cell cycle progression [22]. Zhang et al. [24] reported that Met caused a substan-
tial decrease of cyclin D1 expression in bladder cancer cells. The overexpression 
of oncogene cyclin D1 is positively correlated with chemotherapeutic resistance 
and apoptosis avoidance in squamous cell cancers [23]. The inhibition of CCND1 
expression in aggressive cervical tumor cells resulted in enhanced apoptosis [22].
Met triggered another pro-apoptotic mechanism in cervical carcinoma cells 
via regulation of Bcl-2 (B-cell lymphoma 2) protein family members’ expression 
[22]. Bcl-2 proteins are key players in the regulation of mitochondrial-dependent 
programmed cell death. The activation of BAX protein leads to disruption of 
mitochondrial membrane potential and apoptosis, whereas Bcl-2 acts as an apop-
totic suppressor. The counterbalancing pro- and anti-apoptotic effectors of Bcl-2 
protein family play a crucial role in the regulation of the mitochondrial apoptotic 
cascade within the cell and constitute another important apoptotic checkpoint [25]. 
However, the disturbance of BAX/Bcl-2 pathway may result in the resistance to 
apoptosis by inducing compensatory mechanisms, thereby influencing the efficacy 
of some therapeutic regimens [26]. The exposition of cervical tumor cells to Met 
Figure 1. 
Metformin inhibits glycolytic phenotype of cervical carcinoma cells (↑—activation, Ⱶ—inhibition) [11, 12, 21, 22].
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significantly upregulated BAX transcript. It was found that the expression of BAX 
under hypoxic conditions was greater than in normoxia [22]. Additionally, Met 
downregulated transcript for BCL-2 in HTB-35 cells in both, normoxic and hypoxic 
conditions.
The study using cervical cancer cells with metastatic phenotype cells showed 
that the downregulation of oncogenes/downstream regulatory proteins, together 
with the upregulation of pro-apoptotic BAX/Bcl-2, elucidated mitochondrial-
dependent apoptosis in tumor cells. The obtained data suggest that Met was highly 
effective in facilitating cell death in cervical tumor cells [22], since it exerted its 
effect targeting independent events controlling mitochondrial apoptosis including 
the induction of ROS [11], the regulation of Bcl-2 protein family expression, and 
downregulation of cyclin D1. It should be emphasized that Met induced cell death 
solely in tumor cells, without causing detrimental effects to normal cells [11].
2.2  Metformin regulates TCA cycle supplementation in cervical cancer cells via 
pyruvate dehydrogenase (PDH) complex and generates oxidative stress in 
mitochondria
The reprogrammed metabolism of tumor cells not only meets high energetic 
demands but also provides intermediates for intensive proliferation. Therefore, gly-
colysis and mitochondrial oxidative phosphorylation may operate simultaneously 
in cancer cells. Many tumors may even switch between these pathways accordingly 
to the current requirements. Recent studies showed that most cancer cells have 
metabolically efficient mitochondria to provide intermediates for biosynthesis, 
generate reductive power (nicotinamide adenine dinucleotide phosphate, NADPH), 
and restore cofactor pool (e.g., nicotinamide adenine dinucleotide, NADH). In 
highly proliferating cancer cells, mitochondrial TCA cycle is active enough to 
sustain the biochemical reactions. Currently, the precise regulation of anabolic 
pathways and keeping their activities at adequate level is thought to play a key role 
in determination of “flexible” metabolic phenotype of cancer cells that enables their 
rapid division. Moreover, oxidative phosphorylation (OXPHOS) may represent a 
significant contribution to energy generation within malignant cell. On the other 
hand, inevitable products of OXPHOS are ROS and oxidative stress due to ROS 
overproduction may kill tumor cells [27].
It was demonstrated that the process of detachment of migrating squamous 
cancer cells from extracellular matrix (ECM) results in reprogramed metabolism 
toward glycolysis, particularly by PDH complex inhibition and following suppres-
sion of glucose respiration in mitochondria. Such metabolic phenotype of tumor 
cell enables efficient production of energy without excessive ROS generation. On 
the other hand, the stimulation of PDH activity may lead to increased anoikis 
sensitivity and attenuation of metastatic potential of cancer cells [28].
We found that Met may precisely regulate PDH metabolic checkpoint in cervical 
tumor cells (Figure 2). Met had great potency to activate oxidative decarboxylation 
of pyruvate to acetyl-CoA in HTB-35 cells expressing invasive phenotype, and it 
occurred via activation of PDH complex [11]. PDH complex plays a determinant 
role in the overall glucose disposal within the cell, since it funnels mitochondrial 
TCA cycle instead of lactate formation in cytosol. PDH activity is precisely 
regulated via covalent modification by the action of specific enzyme pyruvate 
dehydrogenase kinase (PDK). Several PDK activators were found to expand potent 
antitumor effect, also in cervical tumor HeLa cells [29]. We showed in aggressive 
cervical cancer HTB-35 cells that Met suppressed both PDK activity and the expres-
sion of gene encoding tumor-specific isoenzyme PDK1 [22]. This finding may 
have practical implications, since the screening strategy for PDK inhibitors should 
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recognize the specificity among the PDK isoenzymes in order to avoid side effects 
in vivo [30]. Under hypoxic conditions inside tumors, the activation of HIF-1α 
decreases mitochondrial metabolism, which prevents the cell from oxidative stress 
and helps cancer cells avoid apoptosis [20, 23]. Our study showed that in aggressive 
cervical cancer cells Met counteracted these metabolic alterations by inhibiting 
PDK1, which is at the same time HIF-1α prime downstream effector. Furthermore, 
Met downregulated PDK1 gene expression also in normoxia [22].
In tumor cells that have functional mitochondria, the generation of oxidative 
stress may become an important therapeutic target [27, 30]. The imbalance of 
metabolic regulation and the resulting overproduction of ROS in mitochondrial 
ETC cause oxidative stress, which, at some point, becomes toxic to cancer cells, 
and that escalation of ROS elicits apoptosis-inducing factors and triggers death 
program through multiple mechanisms. In compliance, it has been newly reported 
that Met significantly increased ROS level, altered apoptosis-associated signaling, 
and induced cell death in human gastric adenocarcinoma cells [31] and human 
cervical cancer HeLa cells [32]. We found that in HTB-35 cervical cancer cells, Met 
caused excessive generation of mitochondrial ROS and elicited apoptosis [11, 22]. 
As shown in [22], the effect of Met was specific to tumor cells, and the formation of 
mitochondrial ROS was not affected in normal cells exposed to Met.
Met concomitantly targeted cytosolic glycolysis and mitochondrial pathways in 
HTB-35 cells, which increased apoptosis and suppressed survival of cervical tumor 
cells under normoxic and hypoxic conditions [22].
2.3  Met restrains glutamine entry into TCA cycle and inhibits cervical tumor 
cell proliferation
Glutamine may provide precursors to feed TCA cycle under limited flux of 
pyruvate from cytosolic glycolysis within tumor cells. The facilitated use of gluta-
mine is a significant metabolic adaptation of cancer cell, besides enhanced glucose 
catabolism, and it provides intermediates sufficient for intensive biosynthesis and 
Figure 2. 
Metformin regulates mitochondrial metabolism of cervical carcinoma cells (↑—activation, Ⱶ—inhibition) 
[11, 13, 22, 27, 30].
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energy production [20]. Glutaminase (GLS) is a key regulator of glutamine entry to 
TCA [33], and the inhibition of the enzyme may suppress tumor cell growth [25].
As shown in [11], the exposition of cervical cancer cells with invasive pheno-
type to Met downregulated the expression of GLS, thereby protecting mitochon-
drial anabolism from additional carbon supply for synthesis of macromolecules. 
Additionally, the effect of Met on GLS expression was specific toward cervical 
cancer cells, and in normal cells drug did not change the expression of the 
enzyme [11].
Glutamine entry to tumor cell not only improves carbon supply for macromol-
ecules buildup, but it also replenishes the pool of cellular NADPH, since the conver-
sion of malate to pyruvate catalyzed by malic enzyme 1 (ME1) is accompanied by 
the reduction of NADP+ (Figure 2). NADPH is used for biosynthesis, but it also 
plays a significant role in the antioxidant protection of tumor cell by reducing 
glutathione molecule. Met downregulated expression of ME1 and alleviated genera-
tion of NADPH in cells, which, in conditions of limited supplementation of HTB-35 
cells with glucose (suppressed expression of GLUTs), resulted in hampering of 
biosynthesis and alleviation of ROS detoxification [11, 22].
Furthermore, Met treatment caused acute drop in ATP concentration in 
HTB-35 cells. This is in compliance with data obtained by Parker et al. [34] who 
demonstrated that non-small cell lung cancer (NSCLC) cells may be uniquely 
sensitized to metabolic stresses by the action of other biguanide, phenformin 
(1-(diaminomethylidene)-2-(2-phenylethyl)guanidine). The inhibition of ATP 
generation may block biosynthesis in cervical tumor cells which results in restrain-
ing of cell proliferation.
2.4  Alterations of fatty acid (FA) de novo synthesis in cervical tumor cells upon 
exposition to Metformin affect cell proliferation
The facilitated fatty acid (FA) de novo synthesis together with upregulated 
glycolysis was recognized as one of the prime metabolic alterations in such tumor 
cells [35]. The enhanced FA biosynthesis meets high demands of rapidly proliferat-
ing malignant cells (generating components for cell membranes and signaling 
molecules). We found that Met decreased unsaturated lipid content in aggressive 
cervical cancer cells (Figure 2). The mechanism of Met action included downregu-
lation of regulatory enzyme elongase 6 (ELOVL6), which catalyzes elongation of 
fatty acid molecule. Met also suppressed stearoyl-CoA desaturase (SCD1), which 
controls desaturation of FA. It was shown by Fritz et al. [36] that pharmacologic 
inhibition of SCD1 activity impaired unsaturated FA synthesis, which resulted 
in decreased proliferation of both androgen-sensitive and androgen-resistant 
prostate cancer cells. The treatment of cervical cancer cell lines [22, 37] with Met 
decreased cervical tumor cell proliferation, but Met did not affect the growth of 
normal cells [11].
2.5  Metformin inhibits epithelial-to-mesenchymal transition (EMT) process 
and migration properties of cervical cancer cells
Emerging data indicate that the enhanced activity of enzymes regulating lipid de 
novo synthesis may contribute to activation of EMT process in tumor cells [36]. The 
activation of EMT program in epithelial cancer cells facilitates tumor progression, 
invasion, and metastasis. It has been shown in independent studies that Met inhibits 
EMT in various cancer cell lines [8, 37]. Recently, it has been reported that Met 
reversed EMT phenotype induced with transforming growth factor beta 1 (TGF-β1) 
in breast, lung, and cervical cancer cells by targeting the mechanisms regulating the 
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expression of E-cadherin. The exposition of tumor cells to Met resulted in suppres-
sion of their metastatic properties [8, 38].
In our study, EMT process was induced upon 48 h incubation of cervical cancer 
cells with 10 ng/mL of cytokine TGF-β1, as described in detail in [17]. HTB-35 cells, 
even unstimulated, expressed mesenchymal-like characteristics, and the incubation 
with TGF-β further enforced expression of mesenchymal marker, vimentin, along 
with enhancement of cell scattering and ability to move [17]. The study showed 
that Met was an effective suppressor of mesenchymal phenotype and, in particular, 
downregulated vimentin in HTB-35 cells (Figure 3). Recently, it was reported by 
Laskov et al. [39] that Met downregulated the expression of vimentin in endome-
trial cancers in vitro and in vivo in diabetic patients. The incubation of cervical 
cancer cell lines with Met reduced cells’ ability to move, as shown using functional 
scratch test in C4-I and HTB-35 cells stimulated with TGF-β1 [17]. Mechanistic 
study revealed that Met inhibited the expression of transcription factors Snail-1, 
ZEB-1, and Twist-1. These mesenchymal markers facilitate EMT progress in cervi-
cal cancer cells.
Cheng and Hao [8] proposed another mechanism of Met action in cervical 
carcinoma cells via inhibition of mTOR/p70s6k signaling pathway and downregula-
tion of glycolytic regulatory protein pyruvate kinase, isozyme M2 (PKM2), in HeLa 
cell line.
In order to clarify the molecular action of Met in cervical tumor cells with 
aggressive characteristics, the effect of the drug was tested in the hypoxic condi-
tions. In cervical cancers, hypoxia and concomitant enhanced lactate formation 
result in acidification of microenvironment, which may promote the ability of 
metastatic cells to rapidly spread in tissue [41]. In such conditions, the activation of 
HIF1α induces its downstream protein carbonic anhydrase IX (CAIX). By regula-
tion of tumor milieu pH, CAIX acts as a survival factor protecting malignant cells 
Figure 3. 
Metformin inhibits TGF-β1-induced EMT phenotype of cervical carcinoma cells (↑—activation,  
Ⱶ—inhibition) [8, 17, 40].
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against enhanced acidification of microenvironment. As a result, lactate damages 
adjacent normal cells and does not harm tumor cells [42]. Due to its relevant role in 
cell invasion, CAIX was proposed as a potential therapeutic target, also in cervi-
cal cancers [41, 42]. We showed that the exposition of HTB-35 cells to Met under 
hypoxia suppressed HIF-1α, which resulted in decreased transcription of CAIX 
gene, thereby alleviating invasive properties of cervical malignant cells [17].
3. In vivo findings related to the effect of Metformin
Recently, numerous beneficial activities of Met were reported. Met was shown to 
improve cardiovascular outcomes in humans [43], and the ability of Met to extend 
life-span in mammals has attracted great attention [44]. Emerging data indicate 
that Met may be applied as adjuvant in therapies aiming at combating diseases with 
high mortality rate, also in cervical cancer [45]. The clinical benefits of the use of 
Met in gynecologic oncology in humans were reviewed by Irie et al. [46] and Imai 
et al. [47]. Met also reduced the incidence of endometrial tumors and improved 
survival of patients with diagnosed local or advanced endometrial cancer [48]. 
Several clinical trials showed the potential of Met to elicit apoptosis in the uterus 
and prostate cancers in humans [49].
The potential pathological effects of Met have been well studied in long 
term in human population. One of the most undesirable effects in the context 
of peculiar metabolic alterations of cancer cell is the enhanced generation 
of lactic acid caused by biguanides. In fact, the application of phenformin 
(1-(diaminomethylidene)-2-(2-phenylethyl)guanidine) was associated with a 
much higher risk of lactic acidosis in patients, than Metformin. Therefore, the 
former drug was withdrawn from clinical use. Currently, the contraindication 
for the use of Met in patients is renal failure, since this group has greater risk of 
lactic acidosis. However, the concerns over lactic acidosis were shown to be largely 
unfounded, unless kidney disease was advanced. Yet, based on the recent data, 
Met can be safely used in patients with mild renal dysfunction, provided that 
patients are monitored appropriately [43, 50].
4. Conclusions
The exposition of aggressive cervical cancer cells to Met restrained the function 
of HIF-1α master regulator and downregulated HIF-1α downstream glycolytic 
genes. Met also downregulated glycolytic phenotype of HTB-35 cells through inhi-
bition of oncogene c-MYC expression, which resulted in impairment of metabolic 
plasticity of cervical tumor cells, especially via downregulation of GLS.
Met precisely regulated PDH and GLS metabolic checkpoints in cervical tumor 
cells. In particular, in tumor cells Met targeted supplementation of mitochondrial 
pathways in pyruvate by downregulation of PDK1 gene expression and decreasing 
PDK activity. As a result, Met effectively enhanced TCA cycle flux in normoxic and 
hypoxic conditions. The downregulation of GLS and ME1 resulted in decreased 
regeneration of NADPH, the factor essential both for biosynthesis and cell protec-
tion against oxidative stress. The metabolic alterations of mitochondrial pathways 
caused by Met caused excessive generation of ROS which led to apoptosis. In 
cervical cancer cells, Met additionally induced apoptosis via upregulation of pro-
apoptotic BAX protein expression and by downregulation of cyclin D1, oncogene 
c-MYC downstream protein. Met exerted its pro-apoptotic effect both in normal 
and decreased oxygen availability. This aspect of Met action may be important 
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when designing anticancer therapies targeting cells in hypoxic milieu inside solid 
tumors.
It is also important to highlight another cellular mechanism of Met action, 
namely, the suppression of EMT process in cervical tumor cells. EMT seems impli-
cated into invasiveness and metastasis of cancer, and Met was able to inhibit EMT 
pathways. In cervical tumor cells stimulated with TGF-β1 as well as in unstimulated 
ones, Met decreased the expression of the main mesenchymal marker vimentin and 
reduced motility of cells. In addition, Met downregulated adaptive enzyme CAIX in 
tumor cells under hypoxia. CAIX promoted migration of malignant cells and acted 
as an important survival factor, and thus it has recently been proposed as therapeu-
tic target in cervical cancers. Met might be considered as a potential factor targeting 
CAIX to hamper cervical tumor invasiveness.
These findings provide a new insight into regulation of glycolysis and mito-
chondrial pathways in cervical tumor cells using nontoxic and well-studied drug, 
Metformin, indicating the future prospect about utilization of this molecule in 
clinical oncological routine. The identification and targeting of specific alterations 
in tumor metabolic pathways may constitute a sole basis to design new precise 
therapeutic strategies in cervical malignancy. To date, very few innovative therapies 
against cervical malignancy are being tested in clinical trials; thus more specific and 
effective intervention is highly required.
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